このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Beijing Tong Ren Tang Chinese Medicine 配当金

配当金基準チェック /46

Beijing Tong Ren Tang Chinese Medicine配当を支払う会社であり、現在の利回りは3.57%で、収益によって十分にカバーされています。

主要情報

3.8%

配当利回り

51%

配当性向

業界平均利回り	3.8%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	HK$0.330
一株当たり利益	HK$0.65
3年後の配当利回り予想	5.6%

最近の配当金アップデート

Recent updates

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Feb 05

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Jan 03

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Sep 28

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Jul 12

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Mar 29

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Apr 28

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Mar 25

Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?

Oct 27

Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 28

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Mar 11

What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Feb 04

Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?

Jan 18

Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?

Dec 29

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Dec 11

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 23

決済の安定と成長

配当データの取得

安定した配当: 3613の配当金支払いは、過去10年間変動性が高かった。

増加する配当: 3613の配当金は過去10年間にわたって増加しています。

配当利回り対市場

Beijing Tong Ren Tang Chinese Medicine 配当利回り対市場

3613 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (3613)	3.8%
市場下位25% (HK)	3.5%
市場トップ25% (HK)	8.2%
業界平均 (Pharmaceuticals)	3.8%
3年後のアナリスト予想 (3613)	5.6%

注目すべき配当: 3613の配当金 ( 3.57% ) はHong Kong市場の配当金支払者の下位 25% ( 3.25% ) よりも高くなっています。

高配当: 3613の配当金 ( 3.57% ) はHong Kong市場の配当金支払者の上位 25% ( 7.77% ) と比較すると低いです。

株主への利益配当

収益カバレッジ: 3613の配当金は、合理的な配当性向 ( 51.1% ) により、利益によって賄われています。

株主配当金

キャッシュフローカバレッジ: 3613は合理的な現金配当性向 ( 62.9% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。

Beijing Tong Ren Tang Chinese Medicine 配当金

配当金 基準チェック /46

主要情報

最近の配当金アップデート

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023

Upcoming dividend of HK$0.33 per share

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.33 per share at 2.1% yield

Upcoming dividend of HK$0.25 per share

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Special Interim Dividend, Payable on 21 October 2022

Recent updates

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023

Now 22% overvalued after recent price rise

Upcoming dividend of HK$0.33 per share

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Wang Chi as an Executive Director and a Member of the Competition Executive Committee

Now 21% overvalued after recent price rise

Full year 2023 earnings: EPS and revenues miss analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces CEO Changes

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 31, 2024

New minor risk - Financial data availability

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Price target decreased by 14% to HK$14.93

Investor sentiment deteriorates as stock falls 16%

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2023 Results on Mar 31, 2024

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Gu Hai Ou as Executive Director, Chairman of Board and Authorised Representative

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2023 Results on Oct 31, 2023

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Resignation of Lin Man as Executive Director, Chief Operating Officer, Member of Competition Executive Committee

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Retirement of Ding Yong Ling as Executive Director and Chairman of the Board

First half 2023 earnings released: EPS: HK$0.32 (vs HK$0.26 in 1H 2022)

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2023 Results on Aug 10, 2023

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.33 per share at 2.1% yield

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Price target increased by 8.0% to HK$14.66

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2022 Results on Oct 31, 2022

Upcoming dividend of HK$0.25 per share

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Special Interim Dividend, Payable on 21 October 2022

High number of new directors

COO & Executive Director recently bought HK$183k worth of stock

Price target decreased to HK$13.57

First half 2022 earnings released

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Feng Li as Executive Director

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2022 Results on Aug 12, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.28 per share

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Final Dividend for the Year Ended 31 December 2021

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2021 Results on Mar 07, 2022

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$178k worth of stock

Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?

First half 2021 earnings released: EPS HK$0.32 (vs HK$0.27 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2020

Investor sentiment improved over the past week

Upcoming dividend of HK$0.24 per share

Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Full year 2020 earnings released: EPS HK$0.65 (vs HK$0.66 in FY 2019)

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 28, 2021

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Appointment of Chen Fei as Executive Director

CEO & Executive Director Huan Ping Zhang has left the company

Full year 2020 earnings released: EPS HK$0.65 (vs HK$0.66 in FY 2019)

Revenue and earnings beat expectations

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2020 Results on Mar 11, 2021

Investor sentiment improved over the past week

New 90-day high: HK$9.58

Beijing Tong Ren Tang Chinese Medicine Company Limited (SEHK:3613) entered into the Sale and Purchase Agreement to acquire 40% stake in Beijing Tong Ren Tang WM Dianorm Biotech Co., Limited from WM Dianorm Biotech Co., Limited for RMB 33.1 million.

配当金基準チェック /46